TNF and inflammatory bowel disease: At present, the administration of several FDA‐approved anti‐TNF‐α monoclonal antibodies (e.g. etanercept, infliximab, adalimumab, certolizumab, golimumab) represents one of the most successful strategies in the clinical treatment of IBD.